10X Genomics Net Worth
10X Genomics Net Worth Breakdown | TXG |
10X Genomics Net Worth Analysis
10X Genomics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including 10X Genomics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of 10X Genomics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform 10X Genomics' net worth analysis. One common approach is to calculate 10X Genomics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares 10X Genomics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing 10X Genomics' net worth. This approach calculates the present value of 10X Genomics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of 10X Genomics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate 10X Genomics' net worth. This involves comparing 10X Genomics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into 10X Genomics' net worth relative to its peers.
Enterprise Value |
|
To determine if 10X Genomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding 10X Genomics' net worth research are outlined below:
| 10X Genomics generated a negative expected return over the last 90 days | |
| 10X Genomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 414.78 M. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Serge Saxonov Sells 5,092 Shares of 10x Genomics, Inc. Stock |
10X Genomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in 10X Genomics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to 10X Genomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
10X Genomics Target Price Consensus
10X target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. 10X Genomics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 17 | Buy |
Most 10X analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand 10X stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of 10X Genomics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure Valuation10X Genomics Target Price Projection
10X Genomics' current and average target prices are 10.69 and 20.14, respectively. The current price of 10X Genomics is the price at which 10X Genomics is currently trading. On the other hand, 10X Genomics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On 10X Genomics Target Price
Know 10X Genomics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 10X Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 10X Genomics backward and forwards among themselves. 10X Genomics' institutional investor refers to the entity that pools money to purchase 10X Genomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Brown Capital Management, Llc | 2024-12-31 | 1.8 M | Assenagon Asset Management Sa | 2024-12-31 | 1.8 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.8 M | State Street Corp | 2024-12-31 | 1.8 M | Voloridge Investment Management, Llc | 2024-12-31 | 1.6 M | Deerfield Management Co | 2024-12-31 | 1.5 M | Two Sigma Investments Llc | 2024-12-31 | 1.3 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.2 M | Fmr Inc | 2024-12-31 | 13.5 M | Ark Investment Management Llc | 2024-12-31 | 11.9 M |
Follow 10X Genomics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.31 B.Market Cap |
|
Project 10X Genomics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.24) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.26) | (0.27) |
When accessing 10X Genomics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures 10X Genomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of 10X Genomics' profitability and make more informed investment decisions.
Evaluate 10X Genomics' management efficiency
10X Genomics has Return on Asset of (0.1277) % which means that on every $100 spent on assets, it lost $0.1277. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2517) %, meaning that it generated no profit with money invested by stockholders. 10X Genomics' management efficiency ratios could be used to measure how well 10X Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.21. The current Return On Capital Employed is estimated to decrease to -0.26. At this time, 10X Genomics' Debt To Assets are most likely to slightly decrease in the upcoming years. The 10X Genomics' current Asset Turnover is estimated to increase to 0.70, while Non Current Assets Total are projected to decrease to roughly 230.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.90 | 6.19 | |
| Tangible Book Value Per Share | 5.73 | 6.01 | |
| Enterprise Value Over EBITDA | (10.96) | (11.51) | |
| Price Book Value Ratio | 2.44 | 2.31 | |
| Enterprise Value Multiple | (10.96) | (11.51) | |
| Price Fair Value | 2.44 | 2.31 | |
| Enterprise Value | 5.7 B | 5 B |
The management strategies employed by 10X Genomics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Enterprise Value Revenue 1.6497 | Revenue | Quarterly Revenue Growth (0.10) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 10X Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on 10X Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 10X Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
10X Genomics Corporate Filings
F4 | 26th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 13th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 12th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10X Genomics Earnings Estimation Breakdown
The calculation of 10X Genomics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of 10X Genomics is estimated to be -0.29 with the future projection ranging from a low of -0.33 to a high of -0.25. Please be aware that this consensus of annual earnings estimates for 10X Genomics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.33 Lowest | Expected EPS | -0.25 Highest |
10X Genomics Earnings Projection Consensus
Suppose the current estimates of 10X Genomics' value are higher than the current market price of the 10X Genomics stock. In this case, investors may conclude that 10X Genomics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and 10X Genomics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 17 | 82.68% | -0.1356 | -0.29 | -1.52 |
10X Genomics Earnings History
Earnings estimate consensus by 10X Genomics analysts from Wall Street is used by the market to judge 10X Genomics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only 10X Genomics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.10X Genomics Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of 10X Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
10X Genomics Earnings per Share Projection vs Actual
Actual Earning per Share of 10X Genomics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering 10X Genomics predict the company's earnings will be in the future. The higher the earnings per share of 10X Genomics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.10X Genomics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as 10X Genomics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of 10X Genomics should always be considered in relation to other companies to make a more educated investment decision.10X Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact 10X Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-13 | 2024-12-31 | -0.1067 | -0.1356 | -0.0289 | 27 | ||
2024-10-29 | 2024-09-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2024-08-08 | 2024-06-30 | -0.48 | -0.32 | 0.16 | 33 | ||
2024-04-30 | 2024-03-31 | -0.5 | -0.5 | 0.0 | 0 | ||
2024-02-15 | 2023-12-31 | -0.36 | -0.41 | -0.05 | 13 | ||
2023-11-02 | 2023-09-30 | -0.46 | -0.79 | -0.33 | 71 | ||
2023-08-03 | 2023-06-30 | -0.4 | -0.53 | -0.13 | 32 | ||
2023-05-03 | 2023-03-31 | -0.37 | -0.44 | -0.07 | 18 | ||
2023-02-15 | 2022-12-31 | -0.31 | -0.15 | 0.16 | 51 | ||
2022-11-02 | 2022-09-30 | -0.46 | -0.37 | 0.09 | 19 | ||
2022-08-08 | 2022-06-30 | -0.39 | -0.57 | -0.18 | 46 | ||
2022-05-04 | 2022-03-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2022-02-16 | 2021-12-31 | -0.09 | -0.16 | -0.07 | 77 | ||
2021-11-03 | 2021-09-30 | -0.2 | -0.15 | 0.05 | 25 | ||
2021-08-04 | 2021-06-30 | -0.26 | -0.1 | 0.16 | 61 | ||
2021-05-05 | 2021-03-31 | -0.27 | -0.11 | 0.16 | 59 | ||
2021-02-17 | 2020-12-31 | -0.23 | -3.87 | -3.64 | 1582 | ||
2020-11-10 | 2020-09-30 | -0.31 | -0.65 | -0.34 | 109 | ||
2020-08-11 | 2020-06-30 | -0.55 | -0.41 | 0.14 | 25 | ||
2020-05-11 | 2020-03-31 | -0.13 | -0.2 | -0.07 | 53 | ||
2020-02-18 | 2019-12-31 | -0.11 | -0.07 | 0.04 | 36 | ||
2019-11-07 | 2019-09-30 | -0.12 | -0.33 | -0.21 | 175 | ||
2019-09-11 | 2019-06-30 | 0 | -0.16 | -0.16 | 0 |
10X Genomics Corporate Management
| James Wilbur | Chief Officer | Profile | |
| Mennah Moustafa | Chief Officer | Profile | |
| Ruth Backer | Chief Officer | Profile | |
| Florian Baumgartner | Senior Manager | Profile | |
| Jonathan Schimmel | VP Operations | Profile | |
| Jim Goodrich | Chief Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.